Skip to main content

Table 1 Demographic and clinical characteristics of patients with early synovitis at initial visit

From: Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis

 

Patient group

Characteristic

RF+ RA (n = 69)

RF- RA (n = 36)

SpA (n = 43)

UA (n = 90)

Caucasian (%)

77

85

94

82

Females (n)

43 (61%)

27 (73%)

27 (63%)

60 (67%)

Age (years)

47 ± 12* †

43 ± 15

38 ± 11*

41 ± 14†

Symptom duration (weeks)

32 ± 18

29 ± 26

45 ± 59

29 ± 19

Swollen joint count

13 ± 9

14 ± 10

2 ± 2

3 ± 4

Total affected joint count

19 ± 12

19 ± 11

5 ± 11

5 ± 7

ESR (mm/hour)

44 ± 27

46 ± 33

36 ± 30

34 ± 29

CRP (mg/dl)

1.8 ± 1.8

2.1 ± 2.2

1.9 ± 3.0

1.7 ± 2.2

Hemoglobin (mg/dl)

13 ± 1.5

13 ± 1.7

13 ± 1.4

13 ± 1.6

Glucose (mg/dl)

109 ± 53

99 ± 19

99 ± 35

97 ± 30

DMARD therapy (%)

41

39

19

12

Prednisone therapy (%)

36

44

26

11

  1. Values are expressed as mean ± SD, unless otherwise stated. * P < 0.001, †P < 0.05, versus like symbols by analysis of variance or χ2 test, with Yates correction where appropriate. CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor; SpA, spondyloarthropathy; UA, undifferentiated arthritis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us